# First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

> **NCT06616259** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Meng Qiu** · enrollment: 452 (estimated)

## Conditions studied

- Colorectal Cancer (CRC)
- Capecitabine
- Cetuximab

## Interventions

- **DRUG:** mCapOX plus Cetuximab
- **DRUG:** mFOLFOX6 plus Cetuximab

## Key facts

- **NCT ID:** NCT06616259
- **Lead sponsor:** Meng Qiu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-26
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 452 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616259, "First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06616259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*